The Motley Fool
21 Nov 2026, 17:17 UTC · 1h ago
Eli Lilly's Next Big Growth Opportunity Could Be Hiding in Plain Sight
Impact · against what's priced in
The clinical success of Zepbound in adolescents is a positive catalyst for Eli Lilly as the market currently does not price in growth beyond a 30% CAGR. The other mentioned tickers experienced price declines unrelated to the content of this article.
- LLY+0.30
Challenges what's priced in
- The price assumes
Sustaining growth above 30% beyond 2026





